Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 3/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098610 | 1.00 | RXFP1 (0.46) | RXFP1VNN1CES2MAOBSRD5A2 | |
| SCHEMBL3946830 | 0.92 | P4HB (0.41) | RXFP1VNN1MAOBGSK3BPTGDR2 | |
| SCHEMBL3946828 | 0.92 | P4HB (0.41) | RXFP1VNN1MAOBGSK3BPTGDR2 | |
| SCHEMBL3946826 | 0.92 | P4HB (0.41) | RXFP1VNN1MAOBGSK3BPTGDR2 | |
| SCHEMBL3941071 | 0.89 | CES2 (0.56) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3940143 | 0.89 | CES2 (0.56) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL10399267 | 0.89 | CES2 (0.56) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3944597 | 0.86 | MAOB (0.55) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3944593 | 0.86 | MAOB (0.55) | CES2MAOBSRD5A2ALDH1A1LMNA | |
| SCHEMBL3940491 | 0.82 | NR1H4 (0.44) | VNN1GSK3BP4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | RXFP1 65/4885VNN1 1184/4885CES2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.